MESP2 Human Pre-designed siRNA Set A

Cat. No.: M1489715

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Visão geral

MESP2 Human Pre-designed siRNA Set A contains three designed siRNAs for MESP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components MESP2 siRNA-1: 5 nmol (HPLC) MESP2 siRNA-2: 5 nmol (HPLC) MESP2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condições de armazenamento de armazenamento

Store at -20°C

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Product Line

biological_products

Application Protocols

Item-specific tested applications, recommended dilutions/amounts, and validated protocols: Not specified for this item; refer to CoA/Spec Sheet.

Note

• As a general resource, users may consult standard RNAi transfection protocols compatible with their cell system and delivery reagent. However, per policy, no protocol claims are made here for this specific item.

Biological Roles

Target gene (literature; not item-specific performance claims)

• MESP2 (Mesoderm Posterior 2) encodes a basic helix–loop–helix (bHLH) transcription factor that operates in presomitic mesoderm during somitogenesis in vertebrates.
• Functional context: Integrates with Notch, Wnt, and FGF signaling axes to regulate segmentation periodicity and somite boundary formation. Controls downstream genes implicated in anterior–posterior somite polarity (literature).
• Developmental timing: Expressed in the anterior presomitic mesoderm in a dynamic, oscillatory pattern aligned with the segmentation clock (literature).
• Cellular processes: Influences mesodermal patterning, cell fate specification within somites, and transcriptional programs specifying sclerotome and dermomyotome derivatives (literature).

Research implications

• Transient reduction of MESP2 expression using siRNA enables dissection of regulatory circuits governing human mesodermal differentiation models (e.g., iPSC-derived mesoderm) and analysis of boundary formation markers (e.g., Mesp-family targets) under defined signaling perturbations.

Note

• The above reflects general biology of MESP2. This product’s knockdown efficiency, strand selection, and off-target profile are Not specified for this item; refer to CoA/Spec Sheet.

Buffer Applications

Item-specific details

• Supplied buffer/formulation: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for siRNA handling buffers (not item-specific)

• Reconstitution: RNase-free water or TE buffer (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0). TE can improve stability for stock storage.
• Working solutions: Dilute into sterile, RNase-free PBS or cell culture medium immediately prior to transfection as required by the chosen delivery reagent.
• pH range: Near-neutral pH (7.0–8.0) maintains RNA integrity; avoid acidic conditions that promote hydrolysis.
• Ionic strength: Low-millimolar Mg2+/Ca2+ can activate nucleases; EDTA chelation in storage buffers mitigates this risk but may be incompatible with certain enzymatic assays.
• Sterility: If sterility is required, prepare under aseptic conditions and use sterile, RNase-free filters/tubes.

Practical recipes (literature)

• TE (1×): 10 mM Tris-HCl, 1 mM EDTA, pH 7.5–8.0 with RNase-free water.
• RNase-free PBS: Prepare with DEPC-treated or nuclease-free water; autoclave and cool before use.

Green Alternatives

Context

• siRNA workflows are inherently aqueous and typically avoid large volumes of hazardous organic solvents, aligning with greener chemistry practices.

Greener choices within RNAi workflows (general/literature)

• Solvent system: Use RNase-free water or TE instead of organic co-solvents.
• Delivery reagents: Prefer biodegradable, low-toxicity transfection reagents when compatible with cell model; minimize solvent carriers.
• Waste minimization: Aliquot to reduce freeze–thaw loss; scale experiments appropriately to reduce consumables.

Alternatives to consider (application-dependent)

• 2° modalities: CRISPRi (dCas9–KRAB) or ASOs can be alternatives for gene suppression; tradeoffs include delivery complexity and off-target spectra (literature).

Illustrative comparison (literature; not item-specific)

• siRNA: transient, aqueous handling, rapid implementation; requires transfection optimization; knockdown reversible.
• shRNA (vector-based): stable expression, suitable for long-term studies; involves plasmid/viral vectors and biosafety considerations.
• CRISPRi: programmable transcriptional repression; requires guide design and expression of effector proteins; potentially broader equipment footprint.

Pharmaceutical Uses

Applicability note

• This product is designated For research use only. No medical or clinical use is intended or implied.

General context (literature; not item-specific)

• In pharmaceutical research, siRNA reagents are used as discovery tools to validate targets, map signaling pathways, and perform mechanism-of-action studies by transiently suppressing gene expression in cell systems.
• Formulation studies in discovery settings may explore carrier systems (lipid nanoparticles, polymers) to optimize intracellular delivery; findings inform subsequent modality selection but are not therapeutic claims.

Item-specific status

• Pharmacopeial status, excipient roles, GMP grade: Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific specifications

• Appearance, exact MW, extinction coefficient, solubility: Not specified for this item; refer to CoA/Spec Sheet.

General/literature values for siRNA (not item-specific)

• Typical length: 19–27 bp duplex with 2-nt 3′ overhangs (e.g., 21-mer) (literature).
• Approximate molecular weight: ~13–15 kDa for a 21-mer duplex without modifications; actual value depends on base composition and modifications (literature).
• Physical form: commonly supplied lyophilized or in aqueous buffer; readily soluble in RNase-free water or TE buffer (pH ~7.5–8.0) (literature).
• UV absorbance: strong at 260 nm; A260 extinction coefficient depends on exact sequence (literature).
• Stability: stable when dry at −20 °C; in solution more stable at ≤−20 °C; multiple freeze–thaw cycles should be avoided to limit degradation (literature).

Practical notes

• For concentration determination by UV, use sequence-specific ε where available; if not, mass-based reconstitution (e.g., to 20–100 µM) is preferred. For this item, sequence-specific constants are Not specified; refer to CoA/Spec Sheet.

Quality and Grades

Item-specific quality information

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Sequence(s), synthesis scale, desalting/HPLC status, and endotoxin testing: Not specified for this item; refer to CoA/Spec Sheet.

General guidance on siRNA quality (not item-specific)

• Purity designations: "Desalted" siRNA is suitable for many cell culture knockdown experiments; HPLC- or PAGE-purified siRNA provides higher purity and is often preferred for sensitive assays or in vivo–adjacent research contexts.
• Modifications: 2′-O-methyl, 2′-F, phosphorothioate linkages, and terminal conjugates can enhance stability and delivery. Any such features for this item are Not specified.
• Performance implications: Higher purity and defined sequence integrity typically yield more consistent knockdown and lower off-target effects.
• Documentation: For validated performance, sequence, and purity data, consult the product’s CoA/Spec Sheet and SDS. Lot-specific QC (e.g., MALDI-TOF mass confirmation, analytical HPLC trace) is commonly provided for oligonucleotides but is Not specified for this item.

Reaction and Applications

Scope for this product type

• This is a functional genomics reagent for RNA interference (RNAi) rather than a classical chemical reactant.

Applications (general/literature, not item-specific)

• Gene silencing: Delivery of the antisense strand into the RNA-induced silencing complex (RISC) guides sequence-specific cleavage/degradation of MESP2 mRNA (target per product name).
• Pathway interrogation: Transient knockdown enables analysis of MESP2-dependent transcriptional programs and segmentation clock components in human cellular models.
• Phenotypic screening: Use across cell panels to link MESP2 expression to morphology, differentiation markers, or reporter outputs.
• Controls: Employ non-targeting siRNA, positive control siRNA (e.g., targeting a housekeeping transcript), and rescue constructs for specificity assessment.

Practical tips

• Design redundancy: Sets often contain multiple duplexes to mitigate sequence-specific off-targets; exact duplex count is Not specified for this item.
• Delivery: Optimize lipid- or electroporation-based delivery by titrating siRNA (e.g., 1–50 nM ranges are common, literature) and reagent ratios. Validate knockdown by RT-qPCR and/or immunoblot.
• Timing: Peak mRNA depletion typically occurs 24–72 h post-transfection; protein knockdown may lag depending on turnover (literature).

Reaction Conditions

Applicability note

• For siRNA, "reaction conditions" map to transfection and knockdown conditions rather than chemical reactions.

General/literature guidance (not item-specific)

• Cell models: Adherent mammalian cell lines often respond well to lipid-mediated delivery; suspension or primary cells may require electroporation.
• siRNA dose: Common screening ranges are 1–50 nM final concentration; optimal dose balances efficacy and off-target minimization. Always perform a titration.
• Timing: Assess mRNA knockdown 24–48 h post-delivery; protein knockdown at 48–96 h depending on protein half-life.
• Media: Use serum-free medium during complex formation if required by the transfection reagent; many modern reagents tolerate serum during transfection.
• Controls: Non-targeting siRNA, transfection reagent only, and a cytotoxicity dye/assay (e.g., resazurin) to monitor viability.
• Readouts: RT-qPCR for MESP2 transcript levels; western blot/ELISA/IF for encoded protein where antibodies are available; luciferase reporters for pathway activity.

Item-specific parameters (dose, reagent, sequences, expected knockdown): Not specified for this item; refer to CoA/Spec Sheet.

Safety and Handling

Item-specific safety data

• GHS classification, pictograms, signal word, H-statements: Not specified for this item; refer to SDS.
• Storage conditions: Store at −20 °C (per Product Data).
• Shipping: Ice chest + ice pads (per Product Data).

General safety guidance for siRNA reagents (not item-specific)

• Hazard profile: Synthetic oligonucleotides are generally considered low hazard; handle using good laboratory practice. Avoid inhalation of powders/aerosols and contact with skin/eyes.
• PPE: Lab coat, safety glasses, disposable nitrile gloves. Change gloves frequently to minimize RNase contamination.
• Incompatibilities: Avoid RNase contamination; keep work surfaces, tips, and tubes RNase-free. Avoid strong acids/bases and nucleases.
• First aid (overview; defer to SDS): In case of eye/skin contact, rinse with water. If inhaled, move to fresh air. If ingested, rinse mouth and seek medical advice.
• Special precautions: Use dedicated RNase-free consumables, clean benches with RNase decontamination solutions, and keep samples on ice during handling to reduce degradation. Avoid repeated freeze–thaw cycles; aliquot upon first reconstitution.

Solvent Selection

Applicability note: siRNA is an aqueous biomolecular reagent rather than a conventional organic-soluble compound. Solvent considerations focus on RNase-free aqueous media for reconstitution and use.

General/literature guidance (not item-specific)

• Primary solvents: RNase-free water or TE buffer (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0). TE can enhance stability during storage by chelating divalent cations that activate nucleases.
• Compatibility: siRNA is incompatible with most organic solvents for functional use; small percentages of ethanol or DMSO may be present in transfection mixtures depending on delivery reagent, but the siRNA itself should be in aqueous buffer.
• Miscibility and pH: Maintain near-neutral pH (7.0–8.0). Avoid low pH (<6) that can promote depurination of RNA bases (literature).
• Filtration: Use 0.22 µm sterile, RNase-free filters only if sterility is required; avoid excessive shear.

Comparison (typical choices)

• RNase-free water: maximizes flexibility for downstream formulation; slightly less storage stability vs TE.
• TE buffer: improved long-term stability; EDTA can interfere with downstream enzymatic reactions requiring Mg2+; dilute prior to such applications.

Storage and Reconstitution

Item-specific instructions (from Product Data)

• Storage: Store at −20 °C.
• Shipping: Ice chest + ice pads.
• Supplied concentration/formulation, recommended stock concentration, and aliquot size: Not specified for this item; refer to CoA/Spec Sheet.

General/literature best practices (not item-specific)

• Upon receipt: If lyophilized, briefly centrifuge to collect material at tube bottom before opening.
• Reconstitution: Use RNase-free water or TE buffer (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0). Typical stock concentrations are 20–100 µM; select based on assay needs.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze–thaw cycles.
• Storage conditions: Store aliquots at −20 °C (short-to-mid term) or −80 °C (long term) in low-adsorption tubes. Protect from repeated temperature cycling and light.
• Thawing: Thaw on ice, mix gently without vortexing to minimize shearing; brief low-speed spin to collect condensate.
• Stability: siRNA is generally stable for months at −20 °C when properly buffered and handled; in working solution (4 °C), use within days.

Always refer to the item’s CoA/Spec Sheet and SDS for any lot-specific instructions.

Structure and Identity

Item-specific facts (from Product Data)

• Product type: Pre-designed siRNA duplex set targeting human MESP2 (Set A)
• SKU: M1489715
• Intended target: MESP2 (human)
• CAS, CID, SMILES, InChIKey, Molecular formula, Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature description of structure (not item-specific)

• siRNA is typically a double-stranded RNA duplex of ~19–27 nucleotides with 2-nt 3′ overhangs (literature).
• Chemical features: ribose-phosphate backbone with 2′-OH groups; bases A, U, G, C arranged in an antisense/sense duplex; may include stabilizing terminal phosphates or modifications depending on design (not specified for this item).
• 2D structural elements (verbal): two antiparallel RNA strands forming an A-form helix; Watson–Crick base pairing in the central region; 5′-phosphate/3′-hydroxyl termini typical for RNA (literature).

Notes

• As an siRNA set, this product comprises one or more duplexes directed to distinct regions of the MESP2 mRNA; exact sequences and any chemical modifications are Not specified for this item; refer to CoA/Spec Sheet.

Synthetic Utility

Not a classical synthetic building block

• As an siRNA duplex set, this product is not generally employed as a reagent or intermediate in organic synthesis.

Utility in experimental design (general/literature)

• Functional genomics tool: Enables pathway dissection by selective, reversible suppression of MESP2 expression, informing retrosynthetic-like logic in biological networks rather than chemical synthesis.
• Assay construction: Serves as an input variable to create knockdown and rescue experimental branches for causality testing in cell-based assays.

Notes

• For chemical synthesis of conjugates (e.g., fluorophore- or ligand-tagged siRNAs), sequence-specific functional handles are required; any such modifications for this item are Not specified.

Target Specificity

Item-specific (from Product Data)

• Target: Human MESP2 (Mesoderm Posterior Protein 2)
• Species: Homo sapiens
• Format: Pre-designed siRNA Set A
• Number of duplexes, individual sequences, modification patterns, and validation data: Not specified for this item; refer to CoA/Spec Sheet.

Notes

• Use appropriate non-targeting and positive control siRNAs and perform rescue experiments for specificity assessment.